Related Experiment Video
Updated: Jul 31, 2025
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
Clinical efficacy of PARP inhibitors in breast cancer
Karan Pandya1, Alyssa Scher1, Coral Omene2
1Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA.
Abstract:
BRCA1 and BRCA2 are key tumor suppressor genes that are essential for the homologous recombination DNA repair pathway. Loss of function mutations in these genes result in hereditary breast and ovarian cancer syndromes, which comprise approximately 5% of cases. BRCA1/2 mutations are associated with younger age of diagnosis and increased risk of recurrences. The concept of synthetic lethality led to the development of PARP inhibitors which cause cell cytotoxicity via the inhibition of PARP1, a key DNA repair protein, in cells with germline BRCA1/2 mutations. Although still poorly understood, the most well-acknowledged proposed mechanisms of action of PARP1 inhibition include the inhibition of single strand break repair, PARP trapping, and the upregulation of non-homologous end joining. Olaparib and talazoparib are PARP inhibitors that have been approved for the management of HER2-negative breast cancer in patients with germline BRCA1/2 mutations. This review article highlights the clinical efficacy of PARP inhibitors in patients with HER2-negative breast cancer in early and advanced settings.
Insights
PARP inhibitors offer a targeted treatment for HER2-negative breast cancer patients with BRCA1/2 mutations. These drugs exploit synthetic lethality, showing clinical efficacy in both early and advanced stages of the disease.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- BRCA1 and BRCA2 are crucial tumor suppressor genes involved in DNA repair.
- Mutations in BRCA1/2 lead to hereditary breast and ovarian cancer syndromes, accounting for about 5% of cases.
- These mutations are linked to earlier diagnosis and higher recurrence rates.
Purpose of the Study:
- To review the clinical efficacy of Poly (ADP-ribose) polymerase (PARP) inhibitors.
- To focus on HER2-negative breast cancer patients with germline BRCA1/2 mutations.
- To highlight their use in both early and advanced disease settings.
Main Methods:
- Review of clinical studies and literature on PARP inhibitors.
- Analysis of treatment outcomes in patients with HER2-negative breast cancer and BRCA1/2 mutations.
- Exploration of proposed mechanisms of action for PARP inhibitors.
Main Results:
- PARP inhibitors demonstrate clinical efficacy in managing HER2-negative breast cancer in patients with germline BRCA1/2 mutations.
- Approved PARP inhibitors include olaparib and talazoparib.
- The review covers efficacy in both early and advanced stages of the disease.
Conclusions:
- PARP inhibitors represent a significant therapeutic advancement for a specific subset of breast cancer patients.
- Understanding the mechanisms of PARP inhibition is key to optimizing treatment.
- Clinical efficacy is established in both early and advanced HER2-negative breast cancer with BRCA1/2 mutations.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:34Inhibition of Cdk Activity